SYMBICORT TURBUHALER 80/4.5UG -60DOSES

KSh2,550.00

  • SYMBICORT combines an ICS, budesonide and a LABA medicine, formoterol. LABA medicines, such as formoterol, when used alone can increase the risk of hospitalizations and death from asthma problems.This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema.
SKU: DP11769 Category:

INDICATIONS.

Asthma

Symbicort Turbohaler is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:

– patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.

or

– patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Symbicort Turbohaler is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

DOSAGE.

Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.

Recommended doses:

Adults (18 years and older): 1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily.

Adolescents (12 – 17 years): 1-2 inhalations twice daily.

In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include Symbicort given once daily, when in the opinion of the prescriber, a long-acting bronchodilator in combination with an inhaled corticosteroid would be required to maintain control.

Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy.

Children (6 years and older): A lower strength (100 micrograms/6 micrograms/inhalation) is available for children 6-11 years.

Children under 6 years: As only limited data are available, Symbicort is not recommended for children younger than 6 years.

B. Symbicort maintenance and reliever therapy

Patients take a daily maintenance dose of Symbicort and in addition take Symbicort as needed in response to symptoms. Patients should be advised to always have Symbicort available for rescue use.

For patients taking Symbicort as reliever, preventative use of Symbicort for allergen-or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.

Symbicort maintenance and reliever therapy should especially be considered for patients with:

• inadequate asthma control and in frequent need of reliever medication

• asthma exacerbations in the past requiring medical intervention

Close monitoring for dose-related adverse effects is needed in patients who frequently take high numbers of Symbicort as-needed inhalations.

Recommended doses:

Adults and adolescents (12 years and older): The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2 inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.

A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.

Children under 12 years: Symbicort maintenance and reliever therapy is not recommended for children.

COPD

Recommended doses:

Adults: 2 inhalations twice daily

ADVERSE EFFECTS.

Thite patches on tongue/in mouth, signs of infection (such as sore throat that doesn’t go away, fever), mental/mood changes (such as nervousness), trouble sleeping, vision problems (such as blurred vision), increased thirst/urination, muscle cramps, shaking (tremors).

Breathing problems/asthma immediately after use.

 

0